US News

How Creative Biolabs Reshapes Next-Generation RNA Drug Development with an "End-to-End Strategy"

As the global biopharmaceutical industry once again reaches a structural turning point, an mRNA technology route extending from sequence design to preclinical research is being re-examined. Whether it is tumor immunotherapy, vaccines for infectious diseases, or treatments for cardiovascular and metabolic diseases, mRNA has become a "must-win battleground" in the R&D pipeline. "Now, mRNA research and development  is no longer just about 'making an mRNA strand,' but rather predicting its structure, translation efficiency and immune stimulation intensity during the design phase," said a technical leader at Creative Biolabs. "The essence of R&D has shifted from trial and error step by step to chain optimization, and speed will determine which enterprises can remain in the game in the coming years." Winning at the Source: Sequence Design as the Foundation of mRNA Vaccine Development One of the most profound lessons for the industry after COVID-19 is that sequences determine everything. From codon optimization and UTR engineering to Cap modifications and secondary structure prediction, these early-stage steps directly impact stability, expression levels, and antigen presentation efficiency. Creative Biolabs' mRNA vaccine development service is now entering this "source capability." Through structure prediction, in vitro transcription system optimization, LNP formula design, and immune response assessment, this platform helps researchers screen out more promising candidate sequences at the early stage. "Many past failures weren't due to incorrect targets—the mRNA simply didn't express well enough," explained a scientist from the project team. "Building a more reliable structural model during sequence design can shorten development time by six to twelve months." RNA-Protein Interaction Analysis: The Hidden Variable Determining mRNA While the industry is still mired in the inertia that "producing mRNA" is enough to move forward, RNA-protein interaction analysis  is becoming a key technology in the new round of competition. The fate of mRNA in the body is often determined by RNA-binding proteins (RBPs): half-life translation efficiency immune activation even tissue distribution Creative Biolabs' workflow integrates CLIP-seq, pull-down assays, and proteomics to reveal how a given mRNA behaves inside cells. In many cases, the effectiveness of mRNA is not constrained by the sequence itself but "kidnapped" by the proteins it binds to, the leader commented. "Such information is crucial before animal experiments but is often overlooked." One-Stop mRNA Therapy Development : Turning Fragmented Steps Into Deliverable Medicines Once sequence design and functional validation are completed, development often gets stuck in the most time-consuming yet crucial steps, such as manufacturing, delivery system design, and safety evaluation. To address this bottleneck, Creative Biolabs has established a complete chain covering: mRNA synthesis and purification LNP formulation development Stability and functional validation PK/PD studies Toxicology and safety assessment Full preclinical delivery "The biggest inefficiency in the industry now is the stitching together of different platforms," the leader pointed out. "What we are trying to do is to free the R&D team from the task of assembling fragments into a functional drug."